Research Consortium Database PDF Print E-mail

THE CENTERPIECE: A Shared Clinical Database for Alzheimer's Research

The Consortium's data coordinating system is a unique resource for Texas - providing a large, common, standardized database to facilitate collaborative studies of Alzheimer’s disease among four of the state's leading medical institutions. The database consists of two major components:

• The Minimum Data Set (MDS) includes cross-sectional clinical and demographic data on more than 1,100 subjects recruited at Consortium member sites between January 2001 and April 2010 and

• The Longitudinal Data Set (LDS) integrates with the MDS and consists of expanded clinical data collected across all Consortium member sites following standardized protocols.

The LDS data will support projects designed to identify genetic factors and biomarkers associated with Alzheimer’s disease in a subset of 800 individuals. Biomarkers are molecular, biological, or physical characteristics that can indicate a specific, underlying physiologic state or disease.

Analysis of the LDS will enable TARC investigators to model changes in cognitive function over time, enabling identification of factors that affect not only risk, but disease progression. The inclusion of individuals diagnosed with mild cognitive impairment (MCI) will facilitate these efforts as well as increase the scientific value of the data derived. The longitudinal and multi-institutional nature of the Consortium’s study design makes it unique among Alzheimer’s disease research efforts. 

Number of Subjects by Diagnosis & Visit Number as of April 2010

Visit #
Diagnosis 1 2 3 4
Alzheimer's disease 685 419 246 28
Cognitively normal 421 299 147 25
Mild Cognitive Impairment 53 0 0 0
Total 1160 718 393 53
 




Alzheimer's Facts

By 2030, all baby boomers will be 65 or older.  That year, the national Alzheimer's Association projects that 7.7 million in that age group will have Alzheimer's.